TITLE

HPV vaccine

AUTHOR(S)
Sibbald, Barbara
PUB. DATE
November 2005
SOURCE
CMAJ: Canadian Medical Association Journal;11/22/2005, Vol. 173 Issue 11, p1310
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduces the experimental human papillomavirus (HPV) vaccine Gardasil developed by Merck & Co. Percentage of all cervical cancer cases attributed to HPV strains 16 and 18; Statistics on cervical cancer cases worldwide as of October 2005; Recommended dosage of the vaccine.
ACCESSION #
18805654

 

Related Articles

  • HPV vaccine promises to fight cervical cancer. Perry, Leah // Drug Topics;3/20/2006, Vol. 150 Issue 6, p20 

    The article introduces a new vaccine that could eliminate the human papillomavirus (HPV), thereby aiding in fighting cervical cancer. During clinical trials of GlaxoSmithKline PLC's vaccine named Cervarix in November 2005, the drug had prevented 90 percent of new infections and all persistent...

  • Increased screening best option for cervical cancer prevention in Thailand.  // PharmacoEconomics & Outcomes News;9/3/2011, Issue 636, p1 

    The article presents the findings of an analysis which showed that human papillomavirus (HPV) vaccines are unlikely to be cost effective in reducing the problem of cervical cancer in Thailand. It references a study by N. Praditsitthikorn and colleagues, published in the September 2011 issue of...

  • DETECCIÓN DE VIRUS PAPILOMA HUMANO EN LA PREVENCIÓN DEL CÁNCER CÉRVICO-UTERINO. PICCONI, MARÍA ALEJANDRA // Medicina (Buenos Aires);2013, Vol. 73 Issue 6, p585 

    Cervical cancer (CC), which is strongly associated to high-risk human papillomavirus (hr-HPV) infection, continues being a significant health problem in Latin America. The use of conventional cytology to detect precancerous cervical lesions has had no major impact on reducing CC incidence and...

  • Update on the Status of HPV Vaccines.  // Immunization Newsletter;2007, Vol. 29 Issue 6, p1 

    The article focuses on human papillomavirus (HPV) vaccines and their efficacy. The vaccine helps in prevention of cervical cancer. Some of the HPV vaccines mentioned are Gardasil, a quadrivalent vaccine formulated by Merck & Co. Inc. and Cervarix, a bivalent vaccine by GlaxoSmithKline. The...

  • Cervical cancer screening & HPV vaccination: a comprehensive approach to cervical cancer control. Basu, Partha; Chowdhury, Debjani // Indian Journal of Medical Research;Sep2009, Vol. 130 Issue 3, p241 

    India with its highest share of global burden of cervical cancer has to implement a population based cervical cancer control program to reduce the number of deaths. There are new screening options available like visual inspection after acetic acid application (VIA) test, single visit approach to...

  • Fewer Than Three Doses of Cervical Cancer Vaccine Effective.  // JNCI: Journal of the National Cancer Institute;Oct2011, Vol. 103 Issue 19, pNP 

    The article reveals that less than three doses of the human papillomavirus (HPV) vaccine Cervarix could be just as effective as the standard three-dose regimen in preventive measures against cervical cancer, according to a study published on September 9, 2011 in the "Journal of the National...

  • Hot Shot. Atkinson, Jim // Texas Monthly;Apr2007, Vol. 35 Issue 4, p54 

    The article offers information on an executive order by Texas governor Rick Perry involving the vaccination of sixth-grade girls against human papillomavirus (HPV), which causes cervical cancer. HPV is a collection of about 100 viruses, 30 of which are passed via sexual contact. The vaccine...

  • Two HPV vaccines get nod in US.  // PharmacoEconomics & Outcomes News;10/31/2009, Issue 590, p2 

    The article reports that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) in the U.S. has recommended Cervarix, a bivalent human papillomavirus (HPV) vaccine from GlaxoSmithKline, and Gardasil, a quadrivalent HPV vaccine from Merck &...

  • CORRECTING and REPLACING Merck Receives Approval to Market GARDASIL(r), ZOLINZA(r) and CUBICIN(r) in Japan.  // Biomedical Market Newsletter;7/5/2011, p28 

    The article reports that Ministry of Health, Labour and Welfare of Japan (MHLW) approved Merck Co. & Inc.'s (MSD) drug marketing of Gardasil®, Zolinza®, and Cubicin®. MSD president for Japan Tony Alvarez says that the approval would help fulfill their mission and deliver growth....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics